Inclusion Criteria:

- Age: 20-80 years old, both inclusive

- ECOG performance status of 0, 1, or 2

- MSKCC risk of favorable or intermediate

- Histologically confirmed renal cell carcinoma

- No ischemic heart disease

- Laboratory findings meet the following criteria:

1. Respiratory function: %VC, 80% and FEV1.0,70%

2. Hematology: white blood cell count4,000/mm3, platelet count100,000/mm3

3. Clinical chemistry: GOT and GPT within the normal range of each medical
institution; total bilirubin <1.5 x ULN

4. Serum creatinin <2.0mg/dl, blood urea nitrogen (BUN) <25mg/dl

5. Echocardiographic estimation of left ventricular ejection fraction is higher
than the lower limit of reference range of each medical institution.

Exclusion Criteria:

- History of any other malignancy

- Central nervous system metastases. However, patients who remain asymptomatic, have no
new or enlarging lesion in the CNS within 6 months of enrollment in this study, and
require no corticosteroids may be enrolled.

- History of cardiac infarction, unstable angina, congestive heart failure, or
symptomatic peripheral vascular disease within 12 months of enrollment

- History of cerebrovascular disorder including transient ischemic attack (TIA)

- Pregnancy or possible pregnancy at any time during the study

- Ongoing grade 2 adverse event prior treatment

- Prior treatment with any anticancer therapy including cytokine therapy such as
interferon-alpha and interleukin-2

- Prior treatment with mTOR inhibitor

- Prior treatment with sunitinib or sorafenib

- Treatment with an test drug in a clinical research within 4 weeks of enrollment in
this study